The pricing benchmark has shifted faster than systems have adapted. In the UK, prices for one-time t...
Read moreA €3 million invoice for a single infusion can dazzle as easily as it alarms. Gene therapies such ...
Read moreThe advent of cell and gene therapies (CGTs) represents a paradigm shift in medicine, offering the p...
Read moreWe're delighted to announce our participation at ISPOR Europe 2024 in Barcelona this November. We'll...
Read moreThis study examines how Advanced Therapy Medicinal Products (ATMPs) demonstrate economic benefit for...
Read moreNICE recommends gene therapy for severe beta-thalassaemia, offering hope for improved quality of lif...
Read moreNew ground-breaking gene therapy for haemophilia B enters NHS England's Innovative Medicines Fund, o...
Read moreNICE recommends Kymriah® for routine NHS use, offering immense benefits for those with resistant B-...
Read moreWe explore CAR T-cell therapy challenges, regulatory approvals, market growth, pricing models, and a...
Read moreSafety signals have sparked vital discussions on patient access to ATMPs, marking a pivotal moment i...
Read more